Metastatic breast cancer is a chemotherapy-responsive disease, and significant palliation of cancer-related symptoms can be achieved with effective treatment. New treatments are needed because patients with metastatic breast cancer commonly out-live the effectiveness of currently available cytotoxic and hormonal treatments. Pemetrexed is a novel antimetabolite that inhibits three enzymes critical in purine and pyrimidine biosynthetic pathways: thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Several phase II studies of pemetrexed have showed objective response rates of more than 30% in minimally pretreated metastatic breast cancer patients and approximately 20% in more heavily pretreated patients. Pemetrexed is associated with limited toxicity when administered with folic acid and vitamin B(12) supplementation and is therefore a promising agent both for palliative treatment of metastatic disease and for incorporation into combination regimens for treating newly diagnosed metastatic and early-stage breast cancer
Pemetrexed: a promising new treatment for breast cancer / Ja, O'Shaughnessy; A., Gennari; Conte, Pierfranco. - In: SEMINARS IN ONCOLOGY. - ISSN 0093-7754. - STAMPA. - 29(Suppl 5):(2002), pp. 275-280.
Data di pubblicazione: | 2002 | |
Titolo: | Pemetrexed: a promising new treatment for breast cancer. | |
Autore/i: | Ja, O'Shaughnessy; A., Gennari; Conte, Pierfranco | |
Autore/i UNIMORE: | ||
Rivista: | ||
Volume: | 29(Suppl 5) | |
Pagina iniziale: | 275 | |
Pagina finale: | 280 | |
Codice identificativo ISI: | WOS:000175729700007 | |
Codice identificativo Scopus: | 2-s2.0-0036261413 | |
Codice identificativo Pubmed: | 12023791 | |
Citazione: | Pemetrexed: a promising new treatment for breast cancer / Ja, O'Shaughnessy; A., Gennari; Conte, Pierfranco. - In: SEMINARS IN ONCOLOGY. - ISSN 0093-7754. - STAMPA. - 29(Suppl 5):(2002), pp. 275-280. | |
Tipologia | Articolo su rivista |
File in questo prodotto:
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris